News / Health

Immune Drugs Hold Hope of 'Clinical Cure' for Melanoma

FILE - Dr. Antonella Tost, Dermatologist University of Miami School of Medicine, examines Michael Casa Nova, 12, for symptoms of skin cancer due to sun exposure, June 15, 2011.
FILE - Dr. Antonella Tost, Dermatologist University of Miami School of Medicine, examines Michael Casa Nova, 12, for symptoms of skin cancer due to sun exposure, June 15, 2011.
Reuters
A new generation of drugs designed to trigger the immune system to fight cancer is offering the prospect of a “clinical cure” for some melanoma skin cancer patients who until a few years ago were more likely to be facing a swift death.
 
Cancer specialists gathering for a European conference at the weekend said the so-called immunotherapy drugs, a class led by Bristol-Myers Squibb's Yervoy, or ipilimumab, have transformed an area of oncology in which until recently doctors barely had time to get to know their patients.
 
Stephen Hodi, assistant professor of medicine at the Dana-Farber Cancer Institute in the United States, said he was cautious about using the term cure, but described recent advances as a “paradigm shift”.
 
At the least, he said, the success of this new generation of medicines means some melanoma patients would now be living with a chronic disease, rather than facing imminent death.
 
“This is a really amazing time ... A few years ago we could never have imagined using the C-word, cure, in melanoma,” he said. “But we are headed that way.”
 
“Ipilimumab opened a door, and now the field is moving extremely fast,” he told Reuters at the European Cancer Congress (ECC) in Amsterdam.
 
Yervoy, approved by regulators in 2011, was hailed as a breakthrough treatment in melanoma after it became the first drug ever to extend survival in patients with advanced forms of the melanoma, the deadliest form of skin cancer.
 
A type of drug known as a human monoclonal antibody, it activates the body's immune system to fight the cancer by targeting a protein receptor called Cytotoxic T-Lymphocyte Antigen 4, or CTLA-4.
 
On average, Yervoy added only about four months of life in pivotal trials, but around 20 percent of patients had an impressively durable response to the drug.
 
Hodi presented new data at the ECC from the largest and longest study of overall survival for patients treated with Yervoy which showed some of them can survive for up to 10 years.
 
Alexander Eggermont of the Institut Gustave Roussy Comprehensive Cancer Center in France, who specializes in the treatment of melanoma, said Hodi's results suggested some patients could be effectively cured of their cancer - a concept known as a “clinical cure” - with the drug helping the immune to keep the disease in check.
 
“Patients apparently can keep residual tumors under control for a long time when the immune system is properly 'reset', and the concept of 'clinical cures' becomes a reality,” he said in a statement to the conference.
 
And with a next generation of immunotherapy drugs - designed to disable proteins called PD1 and PDL1 that prevent the immune system from spotting and attacking cancer cells - already being tested alone and in combination with Yervoy, there is “tremendous promise” in the treatment of melanoma, said Hodi.
 
Bristol-Myers Squibb is conducting late stage trials of its next-generation drug, nivolumab, in advanced melanoma, while rival U.S. drugmaker Merck is developing a competitor, lambrolizumab, which in early-stage trials helped shrink tumors in 38 percent of advanced melanoma patients.
 
Swiss drugmaker Roche's also has a leading contender - MPDL3280A - in this class.
 
“These [Yervoy] survival results could even double or triple with anti-PD1/PDL1 monoclonal antibodies, and metastatic melanoma could become a curable disease for perhaps more than 50 percent of patients over the coming five to 10 years,” Eggermont said.

You May Like

Video VOA Reporter Tours Devastated Peshawar School

Islamist militants wearing military uniforms and strapped with explosives attacked a military run school Tuesday in the northwestern Pakistani city of Peshawar. At least 141 people were killed in the horrific attack, most of them young students. More

Video Sudan School Becomes Target of Aerial Attacks

Dropout rate at an all-time high in South Kordofan state because many schools have been destroyed during 3-year civil war More

Tennessee Songbirds Fly Coop Long Before Tornadoes Arrive

Researchers say birds apparently alerted to danger by sounds at frequencies below range of human hearing More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
US: Response to Sony Hack Will Be Proportionali
X
Aru Pande
December 19, 2014 1:45 AM
The White House says President Barack Obama considers the cyberattack on Sony Corp. a serious national security matter and that the U.S. will counter with an "appropriate response." VOA correspondent Aru Pande reports.
Video

Video US: Response to Sony Hack Will Be Proportional

The White House says President Barack Obama considers the cyberattack on Sony Corp. a serious national security matter and that the U.S. will counter with an "appropriate response." VOA correspondent Aru Pande reports.
Video

Video Sudan School Becomes Target of Aerial Attacks

The school dropout rate is at an all-time high in Sudan's South Kordofan state because many schools have been destroyed during the three-year civil war between the government and SPLA-N rebel forces. Adam Bailes visited Sudan's Nuba Mountains' region and reports many children are simply too scared to go to school
Video

Video Nigerians Fleeing Boko Haram Languish in Camp Near Capital

In its five-year effort to impose Islamic law in northeastern Nigeria, the Boko Haram extremist group has killed thousands of people and forced hundreds of thousands to flee. Some of those who ran for their lives now live in squalor on the edges of the capital, Abuja. Chris Stein reports for VOA.
Video

Video Putin Says Russian Economy Will Emerge Stronger

Russian President Vladimir Putin has said his country's sinking economy will not only recover but also become stronger, despite falling oil prices and Western sanctions over Ukraine. VOA's Daniel Schearf reports.
Video

Video Detained Turkish Journalists Follow Teachings of US-Based Preacher

The Turkish government’s jailing of critical journalists has sparked international condemnation and is being seen as an effort to undermine the followers of an ailing Turkish preacher based in the United States. VOA religion reporter Jerome Socolovsky has more.
Video

Video ‘Anti-Islamization’ Marches Increase Tensions In Germany

Anti-immigrant rallies in Germany have been building in recent weeks, peaking Monday night in the city of Dresden where tens of thousands of people turned out to demonstrate against what they call the ‘Islamization’ of the West. Germany has offered asylum to more Syrian refugees than any other country, and this appears to have set off the protests. Henry Ridgwell reports from London.
Video

Video Aceh Rebuilt Decade After Tsunami, But Scars Remain

On December 26, 2004 there was an earthquake in the Indian Ocean so powerful it caused the Earth’s axis to wobble a few centimeters. Onshore on the island of Sumatra, the resulting tsunami was devastating. A decade later, VOA Correspondent Steve Herman reports from Banda Aceh, Indonesia, where although there is little remaining evidence of the physical devastation, the psychological scars among survivors remain.
Video

Video Refugees Living in Kenya Long for Peace in the Home Countries

Kenya is host to numerous refugees seeking safe haven from conflict. Immigrants from Somalia face challenges in their new lives in Kenya. Ahead of International Migrants Day (December 18) Lenny Ruvaga has more for VOA News from the Kenyan capital.

All About America

AppleAndroid